Pfizer seems to be the center of various conflicting market sentiments according to recent reports. The pharmaceutical giant leans on cost cuts to offset falling revenue, which has helped increase profit. Pfizer has shown impressive resilience, but its
earnings beat was not enough to quell the concerns of investors. Analysts like
Pfizer despite a mixed Q1 performance, and the stock's 7% yield makes it look like a junk bond. Despite scrapping its weight loss pill, the company eyes
smaller drugmakers after the failure. Meanwhile, uncertainty still surrounds how the stock will react to its upcoming earnings. On Wall Street, Pfizer has been featured among billionaire
Ken Fisher's healthcare stock picks with massive upside potential. Still, its recent fall has sparked questions on whether it's the right time to plunge in and buy the dip. However, experts believe Pfizer is undervalued currently and has a potential rebound in the offing. Others caution that its high yield signifies weakness and not strength. There are also concerns about the discontinuation of its obesity drug candidate and what that means for competitors like Eli Lilly and Novo Nordisk.
Pfizer Stocks News Analytics from Tue, 04 Feb 2025 08:00:00 GMT to Fri, 02 May 2025 07:51:00 GMT -
Rating 0
- Innovation -2
- Rumor -5
